1 March 2024 - In 2023, IQWiG found an additional benefit of vutrisiran compared to patisiran sodium based on a study. ...
17 January 2023 - Vutrisiran is approved for the treatment of patients with hereditary transthyretin amyloidosis with stage 1 or ...
3 April 2022 - Bluebird bio is a highly innovative biotechnology company which develops gene therapies for several rare genetic ...
1 February 2022 - Experience from clinical practice with Zolgensma, a gene therapy against certain forms of spinal muscular atrophy in ...
14 December 2021 - Today the EU Parliament passed the EU-HTA regulation for a joint health technology assessment, which includes, ...
4 November 2021 - The Federal Joint Committee (G-BA) today assessed the additional benefit of two active ingredients against very rare, ...
1 March 2021 - The treatment delays permanent ventilation of the children and extends life. In addition, the children develop more ...
24 June 2020 - Novartis is set to launch its one-off gene therapy Zolgensma for the ultra-rare muscle-wasting disease spinal ...
8 July 2019 - New payment models, dedicated investment, and better health technology assessment are among a raft of changes ...
20 May 2019 - Germany, Italy and England using outcomes-based deals. ...